Prostate cancer Changing standard of care in hormone-sensitive disease

Prostate cancer Changing standard of care in hormone-sensitive disease

New results from the STAMPEDE trial strengthen existing evidence that addition of docetaxel chemotherapy to long-term hormone treatment at the initiation of therapy improves survival in men with hormone-sensitive metastatic prostate cancer.

(Visited 5 times, 1 visits today)
7
Like
Save

Comments

Comments are disabled for this post.